The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. / Asmar, Meena; Asmar, Ali; Simonsen, Lene; Gasbjerg, Lærke Smidt; Sparre-Ulrich, Alexander Hovard; Rosenkilde, Mette Marie; Hartmann, Bolette; Dela, Flemming; Holst, Jens Juul; Bülow, Jens.

In: Diabetes, Vol. 66, No. 9, 09.2017, p. 2363-2371.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Asmar, M, Asmar, A, Simonsen, L, Gasbjerg, LS, Sparre-Ulrich, AH, Rosenkilde, MM, Hartmann, B, Dela, F, Holst, JJ & Bülow, J 2017, 'The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor', Diabetes, vol. 66, no. 9, pp. 2363-2371. https://doi.org/10.2337/db17-0480

APA

Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., ... Bülow, J. (2017). The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes, 66(9), 2363-2371. https://doi.org/10.2337/db17-0480

Vancouver

Asmar M, Asmar A, Simonsen L, Gasbjerg LS, Sparre-Ulrich AH, Rosenkilde MM et al. The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes. 2017 Sep;66(9):2363-2371. https://doi.org/10.2337/db17-0480

Author

Asmar, Meena ; Asmar, Ali ; Simonsen, Lene ; Gasbjerg, Lærke Smidt ; Sparre-Ulrich, Alexander Hovard ; Rosenkilde, Mette Marie ; Hartmann, Bolette ; Dela, Flemming ; Holst, Jens Juul ; Bülow, Jens. / The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. In: Diabetes. 2017 ; Vol. 66, No. 9. pp. 2363-2371.

Bibtex

@article{2dd733798be64549941f4c2b24f2118d,
title = "The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor",
abstract = "A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3-30)NH2, was recently identified as an antagonist of the human GIP receptor. This study examined the ability of GIP(3-30)NH2 to antagonize the physiological actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow (ATBF), and lipid metabolism in humans. Eight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on three different occasions during hyperglycemic-hyperinsulinemic clamps with concomitant infusions of GIP, GIP(3-30)NH2, or both GIP and GIP(3-30)NH2 During infusion of GIP(3-30)NH2 alone and in combination with GIP, insulin levels and the total glucose amount infused to maintain the clamp were lower than during GIP alone. In addition, ATBF remained constant during the antagonist and increased only slightly in combination with GIP, whereas it increased fivefold during GIP alone. Adipose tissue triacylglyceride (TAG) and glucose uptake decreased, and the free fatty acid/glycerol ratio increased during the antagonist alone and in combination with GIP. The changes in glucose infusion rates and plasma insulin levels demonstrate an inhibitory effect of the antagonist on the incretin effect of GIP. In addition, the antagonist inhibited GIP-induced increase in ATBF and decreased the adipose tissue TAG uptake, indicating that GIP also plays a crucial role in lipid metabolism.",
keywords = "Journal Article",
author = "Meena Asmar and Ali Asmar and Lene Simonsen and Gasbjerg, {L{\ae}rke Smidt} and Sparre-Ulrich, {Alexander Hovard} and Rosenkilde, {Mette Marie} and Bolette Hartmann and Flemming Dela and Holst, {Jens Juul} and Jens B{\"u}low",
note = "{\circledC} 2017 by the American Diabetes Association.",
year = "2017",
month = "9",
doi = "10.2337/db17-0480",
language = "English",
volume = "66",
pages = "2363--2371",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association",
number = "9",

}

RIS

TY - JOUR

T1 - The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor

AU - Asmar, Meena

AU - Asmar, Ali

AU - Simonsen, Lene

AU - Gasbjerg, Lærke Smidt

AU - Sparre-Ulrich, Alexander Hovard

AU - Rosenkilde, Mette Marie

AU - Hartmann, Bolette

AU - Dela, Flemming

AU - Holst, Jens Juul

AU - Bülow, Jens

N1 - © 2017 by the American Diabetes Association.

PY - 2017/9

Y1 - 2017/9

N2 - A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3-30)NH2, was recently identified as an antagonist of the human GIP receptor. This study examined the ability of GIP(3-30)NH2 to antagonize the physiological actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow (ATBF), and lipid metabolism in humans. Eight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on three different occasions during hyperglycemic-hyperinsulinemic clamps with concomitant infusions of GIP, GIP(3-30)NH2, or both GIP and GIP(3-30)NH2 During infusion of GIP(3-30)NH2 alone and in combination with GIP, insulin levels and the total glucose amount infused to maintain the clamp were lower than during GIP alone. In addition, ATBF remained constant during the antagonist and increased only slightly in combination with GIP, whereas it increased fivefold during GIP alone. Adipose tissue triacylglyceride (TAG) and glucose uptake decreased, and the free fatty acid/glycerol ratio increased during the antagonist alone and in combination with GIP. The changes in glucose infusion rates and plasma insulin levels demonstrate an inhibitory effect of the antagonist on the incretin effect of GIP. In addition, the antagonist inhibited GIP-induced increase in ATBF and decreased the adipose tissue TAG uptake, indicating that GIP also plays a crucial role in lipid metabolism.

AB - A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3-30)NH2, was recently identified as an antagonist of the human GIP receptor. This study examined the ability of GIP(3-30)NH2 to antagonize the physiological actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow (ATBF), and lipid metabolism in humans. Eight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on three different occasions during hyperglycemic-hyperinsulinemic clamps with concomitant infusions of GIP, GIP(3-30)NH2, or both GIP and GIP(3-30)NH2 During infusion of GIP(3-30)NH2 alone and in combination with GIP, insulin levels and the total glucose amount infused to maintain the clamp were lower than during GIP alone. In addition, ATBF remained constant during the antagonist and increased only slightly in combination with GIP, whereas it increased fivefold during GIP alone. Adipose tissue triacylglyceride (TAG) and glucose uptake decreased, and the free fatty acid/glycerol ratio increased during the antagonist alone and in combination with GIP. The changes in glucose infusion rates and plasma insulin levels demonstrate an inhibitory effect of the antagonist on the incretin effect of GIP. In addition, the antagonist inhibited GIP-induced increase in ATBF and decreased the adipose tissue TAG uptake, indicating that GIP also plays a crucial role in lipid metabolism.

KW - Journal Article

U2 - 10.2337/db17-0480

DO - 10.2337/db17-0480

M3 - Journal article

C2 - 28667118

VL - 66

SP - 2363

EP - 2371

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -

ID: 182932994